Abbreviation: AE, adverse event.
aNo signiﬁcant diﬀerence.2 bIncluding arterial and venous thrombotic events.1
You are encouraged to report negative side eﬀects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For additional Important Safety Information, please see the full Prescribing Information.
Reference: GIAPREZA™ (angiotensin II) [prescribing information]. San Diego, CA: La Jolla Pharmaceutical Company; 2017.
Warnings and Precautions The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in the randomized, double-blind, placebo-controlled ATHOS-3 study. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo treated patients in the ATHOS-3 study [13% (21/163 patients) vs. 5% (8/158 patients)]. The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism prophylaxis.
IndicationGIAPREZA™ (angiotensin II) increases blood pressure in adults with septic or other distributive shock.